Adalvo is pleased to announce the addition of Obeticholic Acid Tablets to our product Portfolio, a niche orphan product with strong growth potential.
Our product is being developed in collaboration with one of our strategic partners, based on the reference brand Ocaliva. The product is indicated in the treatment of primary biliary cholangitis (PBC) and is also the first and only approved add on treatment of primary biliary cholangitis (PBC) supported by clinical trial data.
The brand sold approximately $351Mn globally in 2021, having a significant growth potential with Global 3Y CAGR at 15%, according to IQVIA.
With our clearly defined product pathway, dossier readiness is expected within 2023 and we believe Adalvo will be amongst the few Companies to achieve day-1 launch in all major markets.